During his second term, President Trump has bolstered his approach at lowering prescription drug prices in the US through innovative yet unprecedented decisions.
Ron Lanton III, Esq
Advertisement
Ron Lanton III, Esq, Partner at Lanton Law PLLC
Articles by Ron Lanton III, Esq
Ron Lanton III, Esq, provides nuance to the current state of pharmacy sustainability and how the MFN drug pricing policy could impact the industry.
Ron Lanton III, Esq, discusses previous MFN drug pricing policies and why the free US drug market often yields higher patient costs.
Ron Lanton III, Esq, discusses the revamped version of the Trump Administration’s MFN drug pricing policy and why his second term may yield different outcomes.
Advertisement
Latest Updated Articles
Why Trump’s Second Term Is Different for the MFN Drug Pricing PolicyPublished: December 15th 2025 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
CMS Announces 15 New High-Cost Drugs for Medicare Price Negotiation Program
2
Work Pressure Continues to Impact Pharmacists’ Suicide Risk, Mental Health
3
Pharmacists Guide Patients as Prescription Drugs Move Over the Counter
4
AAP Releases Updated Childhood Vaccine Schedule Amid Recent HHS Overhaul
5